Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Preoperative immunotherapy combination strategies in operable ER-positive, HER2-negative breast cancer
2016-004424-38Phase 2Unknown
- Sponsor
- Queen Mary University of London
- Start
- Oct 2017
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes, Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of atezolizumab, cobimetinib, ipatasertib and bevacizumab in breast cancer (4 arms), sponsored by Queen Mary University of London. Primary endpoint: Immune response by GzmB-positive CD8-positive T-cell increase. Status: unknown.
02
Drugs
atezolizumabcobimetinibipatasertibbevacizumab
03
Conditions
breast cancer
Beyond the preview
Go deeper on 2016-004424-38.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2016-004424-38.